Treatment of intraocular retinoblastoma with vincristine and carboplatin

Carlos Rodriguez-Galindo, Matthew W. Wilson, Barrett G. Haik, Thomas E. Merchant, Catherine A. Billups, Nirali Shah, Alvida Cain, James Langston, Mindy Lipson, Larry E. Kun, Charles B. Pratt

Research output: Contribution to journalArticle

125 Scopus citations

Abstract

Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma. Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% ± 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% ± 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.

Original languageEnglish (US)
Pages (from-to)2019-2025
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - May 15 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of intraocular retinoblastoma with vincristine and carboplatin'. Together they form a unique fingerprint.

  • Cite this

    Rodriguez-Galindo, C., Wilson, M. W., Haik, B. G., Merchant, T. E., Billups, C. A., Shah, N., Cain, A., Langston, J., Lipson, M., Kun, L. E., & Pratt, C. B. (2003). Treatment of intraocular retinoblastoma with vincristine and carboplatin. Journal of Clinical Oncology, 21(10), 2019-2025. https://doi.org/10.1200/JCO.2003.09.103